<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7128376/results/search/test_trace/results.xml">
  <result pre="SARS, MERS and common flu; the probable mechanism behind the" exact="infection" post="and its immune response. Further, the current treatment options,"/>
  <result pre="behind the infection and its immune response. Further, the current" exact="treatment" post="options, drugs available, ongoing trials and recent diagnostics for"/>
  <result pre="and nervous system. •There is an urgent need for novel" exact="treatment" post="options for COVID-19. •Indian medicinal plants are likely to"/>
  <result pre="medicinal plants are likely to be potential drugs for the" exact="treatment" post="of COVID-19. Abbreviations ACE2, angiotensin-converting enzyme 2 ACE2-Fc, Angiotensin"/>
  <result pre="receptor binding domain RBM, receptor binding motif RCT, randomized controlled" exact="treatment" post="RdRp, RNA dependent RNA polymerase RNA, Ribonucleic acid ROS,"/>
  <result pre="interrupt human-human contact, isolate patients at early stages, identify and" exact="reduce transmission" post="from the animal source, address crucial mysteries about the"/>
  <result pre="al., 2020). Indian medicinal herbs are a promising field for" exact="treatment" post="of various illnesses (Gomathi et al., 2020). Ayurveda and"/>
  <result pre="infection. Hence, by repurposing the Indian medicinal plants, more innovative" exact="treatment" post="options can be penned down for their role in"/>
  <result pre="hands together to fight against coronavirus by practicing self-hygiene and" exact="social distancing" post="(Balachandar et al., 2020). In this review, the structure,"/>
  <result pre="the structure, immunological influence, mechanism of action of the SARS-CoV-2" exact="infection" post="in the human host cell, the availability of disease-specific"/>
  <result pre="potential use of certain Indian medicinal herbs for the effective" exact="treatment" post="of COVID-19 has been discussed. Through this review, we"/>
  <result pre="predecessor SARS-CoV first emerged in 2002. During its course of" exact="infection" post="from 2002 to 2003, 774 deaths were recorded out"/>
  <result pre="has also been proposed that SARS-CoV-2 mechanism of action in" exact="infection" post="of humans is similar to the SARS. It has"/>
  <result pre="the proteins that are analogous in both viruses. During the" exact="infection" post="of the virus, the most important part is the"/>
  <result pre="the symptoms of COVID-19 as proteasomal inhibitors used for HIV" exact="treatment" post="are being used in treatment of COVID-19 (Fig. 2"/>
  <result pre="proteasomal inhibitors used for HIV treatment are being used in" exact="treatment" post="of COVID-19 (Fig. 2 ). A target for the"/>
  <result pre="as SARS and MERS are particularly adept at evading immune" exact="detection" post="and dampening immune responses. It's not yet clear how"/>
  <result pre="2014). The cytokines, IL-17 recruit monocytes and neutrophils to the" exact="infection" post="site showing inflammation and activates other downstream cascades of"/>
  <result pre="a traditional neutralizing antibody which could be used as a" exact="treatment" post="for the infection. Ultimately, there will be a need"/>
  <result pre="clinical trials to delineate any specific side effects of ACE2-Fc" exact="treatment" post="(Kruse, 2020). Therefore ACE2-Fc might play an important role"/>
  <result pre="2020). Therefore ACE2-Fc might play an important role in the" exact="treatment" post="of SARS-CoV-2, if the function of ACE2-Fc is inhibited"/>
  <result pre="Therefore, more innovative approaches are required to detect this viral" exact="infection" post="at an earlier period. Fig. 3 COVID-19 entry into"/>
  <result pre="of human Coronavirus in CNS through olfactory bulb upon nasal" exact="infection" post="which causes inflammation and demyelination. Further it reaches the"/>
  <result pre="consideration while designing and this could be a promising in" exact="treatment" post="strategies. 8 Recent diagnostic techniques During the SARS and"/>
  <result pre="at that time, it is now essential to develop specific" exact="tests" post="for COVID-19. The viral nucleic acid detection is primarily"/>
  <result pre="to develop specific tests for COVID-19. The viral nucleic acid" exact="detection" post="is primarily used in SARS-CoV-2 diagnosis (Wang et al.,"/>
  <result pre="The viral nucleic acid detection is primarily used in SARS-CoV-2" exact="diagnosis" post="(Wang et al., 2020a, Wang et al., 2020b, Wang"/>
  <result pre="collection of upper respiratory nasopharyngeal (NP) swabs for the diagnostic" exact="tests" post="(CDC, 2020). The CDC detection assay targets the N"/>
  <result pre="(NP) swabs for the diagnostic tests (CDC, 2020). The CDC" exact="detection" post="assay targets the N region and consists of one"/>
  <result pre="as potential problems that may diminish the precision of the" exact="tests" post="(Lippi et al., 2020). Moreover, these tests are also"/>
  <result pre="precision of the tests (Lippi et al., 2020). Moreover, these" exact="tests" post="are also expensive, hence cheaper alternatives have been developed"/>
  <result pre="have been facilitated to detect lung abnormalities in this SARS-CoV-2" exact="infection" post="(Shi et al., 2020; Xu et al., 2020a, Xu"/>
  <result pre="et al., 2020). Therefore, it is essential to conduct molecular" exact="tests" post="and consider travel history and clinical symptoms of the"/>
  <result pre="infected individuals. Hence, the integrated approach of imaging and molecular" exact="diagnosis" post="would help in screening and treating COVID-19 effectively. In"/>
  <result pre="integrated approach of imaging and molecular diagnosis would help in" exact="screening" post="and treating COVID-19 effectively. In order to design these"/>
  <result pre="are no FDA approved drugs for COVID-19 yet. At present," exact="treatment" post="provided to the affected individuals are mainly symptom based,"/>
  <result pre="this disease. The vast majority of the drugs used for" exact="treatment" post="worldwide falls under any of the following classification of"/>
  <result pre="and Drug Administration) and are now officially used for the" exact="treatment" post="of HIV (De Clercq, 2009). 9.4 Anti-inflammatory drugs Huge"/>
  <result pre="Remidesivir, increases the potential of the drug to reduce viral" exact="infection" post="(Stebbing et al., 2020). 9.5 Monoclonal antibodies The virus"/>
  <result pre="a rapidly spreading virus, it is essential to provide timely" exact="treatment" post="for the affected individuals (Zumla et al., 2016). A"/>
  <result pre="Table 2 The detailed report of commercially available drugs in" exact="treatment" post="of COVID–19. Table 2 S. no. Name of drug"/>
  <result pre="This table represents the commercially available drugs used for the" exact="treatment" post="of the various forms of coronaviruses. The viral infections"/>
  <result pre="uncovered during 1972. This antiviral drug is used in the" exact="treatment" post="of hepatitis C. It is usually used in combination"/>
  <result pre="and acts as a nucleotide polymerase inhibitor used for the" exact="treatment" post="of hepatitis C. It was used in combination with"/>
  <result pre="interferon or RBV. This drug was previously used for the" exact="treatment" post="of Zika virus (Cheema et al., 2019). 10.3 Lopinavir/Ritonavir"/>
  <result pre="al., 2016). Currently, it is undergoing clinical trials for Ebola" exact="treatment" post="(Mulangu et al., 2019). Another recent study has shown"/>
  <result pre="μM at half maximal concentration against COVID-19 and blocked viral" exact="infection" post="(Wang et al., 2020a, Wang et al., 2020b, Wang"/>
  <result pre="classified as an anti-malarial drug, has shown potential in the" exact="treatment" post="of avian influenza A (Yan et al., 2013). Chloroquine"/>
  <result pre="μM at half maximal concentration against SARS-CoV-2 and blocked viral" exact="infection" post="by increasing the endosomal pH required for viral fusion"/>
  <result pre="In the case of repurposing the existing drugs, randomized controlled" exact="treatment" post="(RCT) are being carried out by various biotechnological companies"/>
  <result pre="clinical trials that have the potential to treat this viral" exact="infection" post="(Table 3 ). More research may be required in"/>
  <result pre="be required in traditional medicine to utilize them in the" exact="treatment" post="of COVID-19. Table 3 Ongoing clinical trials for COVID–19."/>
  <result pre="of Wuhan University 19. The efficacy and safety of carrimycin" exact="treatment" post="in patients with novel coronavirus infectious disease (COVID-19): a"/>
  <result pre="alpha 1b spray in the prevention of novel coronavirus (COVID-19)" exact="infection" post="in highly exposed medical staffs. recombinant human interferon alpha"/>
  <result pre="35. The efficacy and safety of pirfenidone capsules in the" exact="treatment" post="of severe new coronavirus pneumonia (COVID-19) Pirfenidone – Third"/>
  <result pre="due to viral resistance along with viral latency and recurrent" exact="infection" post="in immune-compromised patients (Sumithira et al., 2012). Among antiviral"/>
  <result pre="bioassay systems, the antiviral compounds have been used for rapid" exact="screening" post="from plant extracts and fractions (Scior et al., 2012)."/>
  <result pre="properties, it may be favorable to consider them for the" exact="treatment" post="of COVID-19. It is clear that standard clinical trials"/>
  <result pre="Since ancient times, Indian herbs have been used as a" exact="treatment" post="and preventive strategy for several diseases, including respiratory viral"/>
  <result pre="is attributed to the fact that COVID-19 is a viral" exact="infection" post="that has been known to have the fastest frequency"/>
  <result pre="host cell, which has resulted in the escalation of the" exact="infection" post="in limited time. Hence, it has become a big"/>
  <result pre="3 days (Should be repeated after 1 month till the" exact="infection" post="persist). Effective against SARS-CoV-2, immune-modulator.    Symptomatic Management for"/>
  <result pre="in all countries continue to make efforts to minimize human" exact="contact" post="by facilitating country wide shutdowns of public places as"/>
  <result pre="been initiated to ensure the safety of the people, like" exact="social distancing" post="and self-quarantine which limits our social interactions. This will"/>
  <result pre="COVID-19 has emerged as the most intense and petrifying viral" exact="infection" post="to be handled by the human race. According to"/>
  <result pre="in all countries continue to make efforts to minimize human" exact="contact" post="by facilitating countrywide shutdowns of public places as well"/>
  <result pre="been initiated to ensure the safety of the people, like" exact="social distancing" post="and self-quarantine which limits our social interactions (Balachandar et"/>
  <result pre="identified in the coming days in India. This increase in" exact="infection" post="was mainly due to the ability of this virus"/>
  <result pre="plants that have been used for several decades in the" exact="treatment" post="of various respiratory conditions. It highlights the pathways that"/>
  <result pre="in Italy, USA, Spain and Germany; hence travel restrictions and" exact="quarantine" post="measures have been placed in severely affected areas. The"/>
  <result pre="illness more often than others, also pregnant women with the" exact="infection" post="had did not pass the infection to their unborn"/>
  <result pre="pregnant women with the infection had did not pass the" exact="infection" post="to their unborn babies (Wu and McGoogan, 2020; Chen"/>
  <result pre="the Asian populations are more susceptible to acquire this COVID-19" exact="infection" post="when compared to the other races populations (Xu, 2020)."/>
  <result pre="hands together to fight against coronavirus by practicing self-hygiene and" exact="social distancing." post="The following is the supplementary data related to this"/>
  <result pre="in viral target cells in the respiratory epitheliumJ. Virol.8720136150616010.1128/JVI.03372-1223536651 BlanchardJ.E.EloweN.H.HuitemaC.FortinP.D.CechettoJ.D.EltisL.D.BrownE.D.High-throughput" exact="screening" post="identifies inhibitors of the SARS coronavirus main proteinaseChem. Biol.1120041445145310.1016/j.chembiol.2004.08.01115489171"/>
  <result pre="with atypical pneumonia after visiting WuhanEmerg. Microbes Infect.9202022123631987001 ChanJ.F.W.YipC.C.Y.ToK.K.W.TangT.H.C.WongS.C.Y.LeungK.H.FungA.Y.F.NgA.C.K.ZouZ.TsoiH.W.Improved molecular" exact="diagnosis" post="of COVID-19 by the novel, highly sensitive and specific"/>
  <result pre="Clin. Microbiol.202010.1128/JCM.00310-20 CheemaS.U.R.RehmanM.S.HussainG.CheemaS.S.GilaniN.Efficacy and tolerability of sofosbuvir and daclatasvir for" exact="treatment" post="of hepatitis C genotype 1 &amp;amp; 3 in patients"/>
  <result pre="ChenJ.LauY.F.LamirandeE.W.PaddockC.D.BartlettJ.H.ZakiS.R.SubbaraoK.Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV)" exact="infection" post="in senescent BALB/c mice: CD4+ T cells are important"/>
  <result pre="Virol.8420101289130110.1128/JVI.01281-0919906920 ChenH.GuoJ.WangC.LuoF.YuX.ZhangW.LiJ.ZhaoD.XuD.GongQ.Clinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
  <result pre="acute respiratory syndrome coronavirusBiochem. Pharmacol.7520081601160910.1016/j.bcp.2008.01.00518313035 ChuC.ChengV.HungI.WongM.ChanK.H.ChanK.S.KaoR.PoonL.WongC.GuanY.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax59200425225610.1136/thorax.2003.01265814985565 CinatlJ.MorgensternB.BauerG.ChandraP.RabenauH.DoerrH.Treatment of"/>
  <result pre="and renal passage and their use to treat or prevent" exact="infection" post="by coronaviruseshttps://europepmc.org/article/pat/wo20040938882005 ContiniA.Virtual screening of an FDA approved drugs"/>
  <result pre="their use to treat or prevent infection by coronaviruseshttps://europepmc.org/article/pat/wo20040938882005 ContiniA.Virtual" exact="screening" post="of an FDA approved drugs database on two COVID-19"/>
  <result pre="on two COVID-19 coronavirus proteinsChem Rxiv202010.26434/chemrxiv.11847381.v1 CoonJ.T.ErnstE.Andrographis paniculata in the" exact="treatment" post="of upper respiratorytract infections: a systematic review of safety"/>
  <result pre="a systematic review of safety and efficacyPlanta Med.70200429329810.1055/s-2004-81893815095142 CordesA.K.HeimA.Rapid random-access" exact="detection" post="of the novel SARS-coronavirus-2 (SARS-CoV-2, previously 2019-nCoV) using an"/>
  <result pre="of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary" exact="infection" post="of miceJ. Immunol.17320044030403910.4049/jimmunol.173.6.403015356152 GomathiM.PadmapriyaS.BalachandarV.Drug studies on Rett syndrome: from"/>
  <result pre="RielD.De JongT.ItamuraS.ChanK.-H.Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaquesNat. Med.10200429029310.1038/nm100114981511 HabibzadehP.StonemanE.K.The novel coronavirus: a bird’s eye"/>
  <result pre="for the new coronavirusLancet395202094910.1016/S0140-6736(20)30419-0 JinY.H.CaiL.ChengZ.S.ChengH.DengT.FanY.P.FangC.HuangD.HuangL.Q.HuangQ.A rapid advice guideline for the" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia"/>
  <result pre="new coronavirusLancet395202094910.1016/S0140-6736(20)30419-0 JinY.H.CaiL.ChengZ.S.ChengH.DengT.FanY.P.FangC.HuangD.HuangL.Q.HuangQ.A rapid advice guideline for the diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)Military."/>
  <result pre="receptors for influenza a virus entryJ. Virol.94202010.1128/JVI.01357-19 KawaseM.ShiratoK.van der HoekL.TaguchiF.MatsuyamaS.Simultaneous" exact="treatment" post="of human bronchial epithelial cells with serine and cysteine"/>
  <result pre="Res.75200717918710.1016/j.antiviral.2007.03.00317428553 KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of chloroquine against human coronavirus OC43" exact="infection" post="in newborn miceAntimicrob. Agents Chemother.5320093416342110.1128/AAC.01509-0819506054 KhanM.Y.KumarV.Mechanism &amp;amp; inhibition kinetics"/>
  <result pre="coronavirus circulation in the United States 2014–2017J. Clin. Virol.1012018525610.1016/j.jcv.2018.01.01929427907 KimI.LeeJ.E.KimK.H.LeeS.LeeK.MokJ.H.Successful" exact="treatment" post="of suspected organizing pneumonia in a patient with Middle"/>
  <result pre="the novel coronavirus originating in Wuhan, ChinaF1000Res920207210.12688/f1000research.22211.232117569 LeiP.FanB.MaoJ.WangP.Comprehensive analysis for" exact="diagnosis" post="of novel coronavirus disease (COVID-19) infectionJ. Inf. Secur.202010.1016/j.jinf.2020.03.016 LewinsohnD.M.BowdenR.A.MattsonD.CrawfordS.W.Phase"/>
  <result pre="(COVID-19) infectionJ. Inf. Secur.202010.1016/j.jinf.2020.03.016 LewinsohnD.M.BowdenR.A.MattsonD.CrawfordS.W.Phase I study of intravenous ribavirin" exact="treatment" post="of respiratory syncytial virus pneumonia after marrow transplantationAntimicrob. Agents"/>
  <result pre="Pharma col.9201863510.3389/fphar.2018.00635 LippiG.SimundicA.M.PlebaniM.Potential preanalytical and analytical vulnerabilities in the laboratory" exact="diagnosis" post="of coronavirus disease 2019 (COVID-19)Clin. Chem. Lab. Med.202010.1515/cclm-2020-0285 LiuD.X.FungT.S.ChongK.K.-L.ShuklaA.HilgenfeldR.Accessory"/>
  <result pre="main active constituents Wogonin, Baicalein and BaicalinCancer Treat. Rev.352009576810.1016/j.ctrv.2008.09.00519004559 LoeffelholzM.J.TangY.W.Laboratory" exact="diagnosis" post="of emerging human coronavirus infections- the state of the"/>
  <result pre="coronavirus infections- the state of the artEmerg. Microbes. Infect.202012610.1080/22221751.2020.1745095 LuH.Drug" exact="treatment" post="options for the 2019-new coronavirus (2019-nCoV)Biosci. Trends.202010.5582/bst.2020.01020 LuR.ZhaoX.LiJ.NiuP.YangB.WuH.WangW.SongH.HuangB.ZhuN.Genomic characterisation"/>
  <result pre="Scientist. Published on 24th March, 20202020 McIntoshK.KurachekS.C.CairnsL.M.BurnsJ.C.GoodspeedB.Treatment of respiratory viral" exact="infection" post="in an immunodeficient infant with ribavirin aerosolAm. J, Dis."/>
  <result pre="play a dominant role in fertilityInt. J. Mol. Sci.14102013210712108610.3390/ijms14102107124152441 PandeyA.BigoniyaP.RajV.PatelK.K.Pharmacological" exact="screening" post="of Coriandrum sativum Linn. for hepatoprotective activityJ. Pharm. Bioallied."/>
  <result pre="inhibitorsInt. J. of Pharm. Sci. Rev. Res.252014315318 RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet3952020303110.1016/S0140-6736(20)30304-431908280 RossignolJ.-F.Nitazoxanide, a new drug"/>
  <result pre="acute respiratory diseaseLancet3952020303110.1016/S0140-6736(20)30304-431908280 RossignolJ.-F.Nitazoxanide, a new drug candidate for the" exact="treatment" post="of Middle East respiratory syndrome coronavirusJ. Infect. Public. Health.9201622723010.1016/j.jiph.2016.04.00127095301"/>
  <result pre="Immunol.20201810.1038/s41423-020-0400-431611651 TalbotP.J.ÉkandéS.CashmanN.R.MounirS.StewartJ.N.Neurotropism of human coronavirus 229ECoronaviruses1994339346 TanE.L.OoiE.E.LinC.Y.TanH.C.LingA.E.LimB.StantonL.W.Inhibition of SARS coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugsEmerg. Infect. Dis.10200458110.3201/eid1004.03045815200845"/>
  <result pre="activitiesPharm. Biol.47200942242910.1080/13880200902800196 VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.220056910.1186/1743-422X-2-6916115318 WalkerL.M.BurtonD.R.Passive immunotherapy of viral infections: ‘super-antibodies’"/>
  <result pre="against Ebola virus in rhesus monkeysNature531201638138510.1038/nature1718026934220 World Health Organization (WHO)Laboratory" exact="testing" post="of 2019 novel coronavirus (2019-nCoV) in suspected human caseshttps://apps.who.int/iris/handle/10665/3306762020"/>
  <result pre="Saudi Arabiahttps://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/2020 World Health Organization (WHO)Surveillance case definitions for human" exact="infection" post="with novel coronavirus (nCoV)https://apps.who.int/iris/handle/10665/3303762020 WuZ.McGooganJ.M.Characteristics of and important lessons"/>
  <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res.23201330030210.1038/cr.2012.16523208422 YangY.XiongZ.ZhangS.YanY.NguyenJ.NgB.LuH.BrendeseJ.YangF.WangH.Bcl-xL inhibits T-cell apoptosis"/>
  <result pre="SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19" exact="treatment" post="optionJ. Med. Virol.202010.1002/jmv.25729 YarnellE.Herbs for viral respiratory infectionsAltern. Complement."/>
 </snippets>
</snippetsTree>
